<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646360</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024976</org_study_id>
    <secondary_id>HD43099</secondary_id>
    <nct_id>NCT00646360</nct_id>
  </id_info>
  <brief_title>Effects of Prenatal DHA Supplements on Infant Development</brief_title>
  <official_title>Effects of Prenatal DHA Supplements on Infant Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our research is about the significance of polyunsaturated fatty acids (PUFAs) for human&#xD;
      development. Specifically, we will assess the effect of docosahexanoic acid (DHA)&#xD;
      supplementation during pregnancy on infant growth and development through a randomized&#xD;
      controlled intervention trial in Cuernavaca, Mexico. This is a collaborative effort between&#xD;
      the Rollins School of Public Health, Emory University, the Instituto Nacional de Salud&#xD;
      Publica (INSP) and the Instituto Mexicano del Seguro Social (IMSS), Cuernavaca, Mexico.&#xD;
      Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks&#xD;
      gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until&#xD;
      delivery. The main study outcomes include a) birth outcomes: birth size, gestational age,&#xD;
      cord blood levels of DHA and neurodevelopment b) maternal blood and breast milk DHA levels at&#xD;
      1 and 3 mo post-partum) c) postnatal growth and development during the first 5 years of age&#xD;
      and d) infant DHA status at 3, 12 and 18 mo. All data collection is carried out at the study&#xD;
      headquarters (IMSS) except for home environment that is assessed during home visits. Physical&#xD;
      growth (length, weight, and head circumference) and infant and child development (visual and&#xD;
      auditory evoked potentials, visual attention, Bayley scales of infant development, McCarthy&#xD;
      child development score, Hearts and Flowers stroop test, and other computerized child&#xD;
      development tests) are measured at birth, 1, 3, 6, 9, 12, 18, 24, 36 mo and at 4 and 5 years&#xD;
      of age by trained workers. Data are also obtained on socioeconomic status, obstetric history,&#xD;
      maternal diet, anthropometry and intelligence, quality of home environment and infant feeding&#xD;
      practices. Data analysis will include group comparisons (intent-to-treat) after ensuring&#xD;
      effectiveness of randomization, and structural equation modeling to examine the various&#xD;
      pathways by which DHA supplementation during pregnancy affects child growth and development.&#xD;
      The findings of this project will contribute significantly to our understanding of the&#xD;
      functional consequences of DHA supplementation during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birth size and gestational age</measure>
    <time_frame>Birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant growth and development in the first 5 years of life</measure>
    <time_frame>first 5 years of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune function and morbidity</measure>
    <time_frame>first 6 mo of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive outcomes at age 7 y</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1094</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docosahexonic acid (400 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>400 mg/d of docosahexanoic acid (DHA) during pregnancy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Martek Algal DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets daily during pregnancy</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Specially formulated by Martek Biosciences</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-22 weeks pregnant (based on last menstrual period)&#xD;
&#xD;
          -  18 - 35 years old&#xD;
&#xD;
          -  Resident of Cuernavaca who intends to deliver at the IMSS General Hospital I and&#xD;
             remain in the area for the 2 years following recruitment&#xD;
&#xD;
          -  Intends to predominantly breastfeed infant until 3 months of age&#xD;
&#xD;
          -  Agrees to participate with informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  High risk pregnancy: If documented in the clinical record at recruitment and will&#xD;
             include history and prevalence of abruptio placentae, any serious bleeding episode in&#xD;
             the current pregnancy, gestational diabetes, pregnancy induced hypertension, maternal&#xD;
             toxoplasmosis infection during pregnancy, coagulation disorders, thrombocytopenia or&#xD;
             chronic vascular, renal or systemic disease and drug use.&#xD;
&#xD;
          -  Lipid metabolism (hyperlipidemia) and/or absorption disorders&#xD;
&#xD;
          -  Regular intake of fish oil or DHA supplements during pregnancy&#xD;
&#xD;
          -  Chronic use of medication for illnesses like epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usha Ramakrishnan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMSS General Hospital I</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Usha Ramakrishnan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>birth size, gestational age, development, child growth,</keyword>
  <keyword>prenatal nutrition, DHA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

